Moneycontrol PRO

HomeNewsBusinessMoneycontrol ResearchGland Pharma’s new product play for FY22 holds a lot of promise

Trending Topics

Gland Pharma’s new product play for FY22 holds a lot of promise

While the US market is still expected to clock 18-20 per cent growth for Gland Pharma in FY22, the company’s foray into non-US markets would accelerate growth in the medium term

Anubhav Sahu

July 22, 2021 / 19:11 IST

Gland Pharma’s new product play for FY22 holds a lot of promise

Gland Pharma Limited | The share price has surged 124 percent to 3,367.05 on July 1, 2021, from its issue price of Rs 1,500. It was listed on exchanges on November 20, 2020, with an issue size of Rs 6,480 crore.

Watch Webinar

PRO Panorama

Moneycontrol Pro Panorama | Easy banking or risky banking?

Oct 3, 2025 / 03:35 PM IST

In Moneycontrol Pro Panorama October 3 edition: RBI surveys show tax cuts boosted consumer confidence, economic and social impact ...
Read Now
PRO Weekender

Moneycontrol Pro Weekender | When the Ground Shifts

Sep 27, 2025 / 10:00 AM IST

In a week where the fault lines of markets, technology, and policy all seemed to move at once, the only certainty is that change i...
Read Now

Unlock This Article

Are you a PRO subscriber? Sign In

What Do You Get

Ad free Experience

Seamless navigation, faster responses.
Expert Perspective

Explore 230+ exclusive editorials every month
+

Uncover Insights from World-Renowned Experts and Journalists
Actionable Insights

40+ weekly investment ideas + 3 to 4 daily technical calls
Virtual Events

Exclusive Live Webinars for Expert Trading & Investment Strategies!
Newsletters

Stay ahead with daily and weekly insights

Unlock exclusive discounts

Disclosure & Disclaimer

This Research Report / Research Recommendation has been published by Moneycontrol Dot Com India Limited (hereinafter referred to as “MCD”) which is a registered Investment Advisor under the Securities and Exchange Board of India (Investment Advisers) ...Read More